Sangamo Therapeutics (SGMO)

• Market cap: $55.9M
• 1 day: 13.26%
• 5 days: -26.35%
• 1 month: -48.1%
• 3 months: -76.23%
• 6 months: -76.66%
• Year to date: -69.22%
• 1 year: -81.79%
• 5 years: -98.84%
• 10 years: -97.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.

Employees: 142